Bacterial l-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukaemia for over 30 y. However, their use is limited owing to the glutaminase activity of the administered enzymes, which results in serious side effects. In contrast, l-asparaginase from Erwinia carotovora exhibits low glutaminase activity at physiological concentrations of l-asparagine and l-glutamine in the blood. Recombinant Er. carotovora l-asparaginase was crystallized in the presence of l-glutamate by the hangingdrop vapour-diffusion method using 10 mg ml À1 purified enzyme, 16-18%(w/v) PEG 3350 and 0.2 M NaF. X-ray diffraction data were collected to 2.6 Å at 293 K using an in-house rotating-anode generator. The crystals belong to the monoclinic P2 1 space group, with unit-cell parameters a = 78.0, b = 112.3, c = 78.7 Å , = 101.9 and a homotetramer in the crystallographic asymmetric unit. A molecular-replacement solution has been found and refinement is currently in progress. The crystal structure may provide leads towards proteinengineering efforts aimed at safer asparaginase administration in leukaemia treatment.
Introduction
l-Asparaginase (l-asparagine amidohydrolase; EC 3.5.1.1) is an enzyme that catalyzes the conversion of l-asparagine to l-aspartate and ammonia and to a lesser extent the formation of l-glutamate from l-glutamine. Similar to asparaginases, enzymes known as glutaminase-asparaginases that are able to catalyze the hydrolysis of both l-asparagine and l-glutamine with comparable efficiency have been identified. Crystallographic structures of bacterial l-asparaginases from Escherichia coli and Erwinia chrysanthemi (Swain et al., 1993; Aghaiypour et al., 2001; Sanches et al., 2003; Lubkowski et al., 2003; Kozak et al., 2002) and l-glutaminase-asparaginases from Pseudomonas 7a and Wolinella succinogenes (Lubkowski et al., 1994 (Lubkowski et al., , 1996 have provided insights into the active site of these enzymes. Moreover, plant-type asparaginases have been identified and the sequence similarities of one of them, namely Lupinus luteus L1A, to the E. coli periplasmic asparaginase EcAIII have been reported (Borek et al., 2004) .
Administration of l-asparaginase has been found to reduce l-asparagine levels in the blood and to selectively inhibit malignant growth (Duval et al., 2002) . This is explained by the fact that certain tumours, especially acute lymphoblastic leukaemia (ALL) tumour cells, have a decreased or completely absent activity for asparagine synthase and hence are nutritionally dependent on an external supply of l-asparagine for growth. Accordingly, l-asparaginases from E. coli and Er. chrysanthemi have been used as therapeutic agents since the early 1970s. However, asparaginase-based therapy often produces side effects, including hypersensitivity reactions, leukopenia, neurological seizures, pancreatitis and hyperglycaemia. The toxicity of the administered asparaginases is partially attributed to an intrinsic glutaminase activity of the enzymes, which results in l-glutamine depletion in the blood. Although l-asparaginases from Er. chrysanthemi and E. coli show the lowest toxicity of the asparaginases with known anti-tumour activities, the need for new asparaginases, especially from Erwinia strains, is of great interest for biomedicine and biotechnology. Elimination of the glutaminase activity would result in better and safer asparaginases for clinical use. l-Asparaginase from Er. carotovora (75 and 45% sequence identity to Er. chrysanthemi and E. coli l-asparaginases, respectively) has been found to possess a relatively low glutaminase activity (2.6% of the asparaginase activity compared with 10% in Er. chrysanthemi l-asparaginase), thus providing a promising starting point for protein-engineering studies of the active site of the enzyme (Krasotkina et al., 2004) . We have initiated structural studies on Er. carotovora asparaginase and report here the crystallization of the enzyme in the presence of glutamate and the preliminary characterization of the crystals.
Experimental methods
The protein was expressed and purified as described previously (Krasotkina et al., 2004) . The pure protein (MW 34 kDa in SDS-PAGE gel) was concentrated to 10 mg ml À1 in 10 mM phosphate buffer pH 7.0. Initial crystallization trials were carried out using the hanging-drop vapour-diffusion method at 289 K and Hampton Crystal Screen I. The drops contained 2 ml protein solution and an equal volume of precipitant solution. Inspection of the drops after 1 d revealed the presence of needle-like crystals in several conditions in which PEG was used as the main precipitant. The PEG/Ion screen from Hampton Research was subsequently used to identify the optimum salt condition for the improvement of the crystals. Rod-like crystals and needles appeared under various conditions. In addition, thin plate-like crystals were found to grow in the presence of 0.2 M NaF, KF or NH 4 F (conditions 1, 2 and 3 of the PEG/Ion screen, respectively). For an initial evaluation of their quality, crystals were placed in quartz capillaries and exposed to X-rays produced by a Rigaku RU-200 generator operated at 50 kV and 100 mA and equipped with Osmic confocal mirrors and a copper target (Cu K; = 1.5418 Å ). Diffraction data were recorded on a MAR345 imaging-plate detector. The rod-like crystals were found to diffract poorly ($10 Å ). A plate-like crystal was found to diffract to approximately 4 Å resolution and the growth conditions of this crystal were chosen for further optimization. Prior to crystallization, the protein was mixed with sodium l-glutamate solution pH 8.5 to a final concentration of 10 mM. Crystals suitable for crystallographic analysis and structure determination were subsequently obtained in the presence of 16-18%(w/v) PEG 3350, 0.2 M NaF (Fig. 1) . Different pH values had no effect on the appearance of the crystals. Data to 2.6 Å resolution were collected at room temperature (exposure time 5 min, crystal-to-detector distance 225 mm) from a single crystal. The crystal was translated in the beam twice during data collection and a total of 86 images (1.5 rotation for each image) were recorded. Raw intensities were integrated, scaled and merged using the XDS program suite (Kabsch, 1993) . Data statistics are given in Table 1 .
Results and discussion
Crystals of Er. carotovora l-asparaginase belong to the monoclinic space group P2 1 , with unit-cell parameters a = 78.0, b = 112.3, c = 78.7 Å , = 101.9 . Assuming the presence of four molecules (34 kDa each) in the crystallographic asymmetric unit, the Matthews coefficient V M (Matthews, 1968 ) is 2.48 Å 3 Da À1 , corresponding to a solvent content of 50.0%. This is in agreement with the presence of homotetramers, as found in the crystals of other asparaginases. Different combinations of salts and PEG 3350 were used to obtain crystals of Er. carotovora asparaginase that were suitable for crystallographic analysis. Of the salts tried, the use of NaF provided the best crystals for further crystallographic studies. The crystal was sensitive to X-rays, as reflected by the relatively high overall R merge (12.9%). In order to collect a complete data set, the crystal was translated twice to overcome the deterioration of the diffraction arising from radiation damage.
Crystal structure determination has been pursued by molecular replacement with the program AMoRe (Navaza & Saludjian, 1997 ) using a polyalanine model of Er. chrysanthemi l-asparaginase (PDB code 1hfw). Data in the 8.0-3.5 Å resolution range were used for the rotation and translation searches. The top solution from the rotation function was used in the translation search to locate the first of the four molecules. A correlation coefficient of 59.1% and an R factor of 40.0% were obtained when all four molecules were positioned. Inspection of crystal-packing contacts revealed no major clashes. Rigid-body refinement in CNS v.1.1 (Brü nger et al., 1998) Typical crystals of Er. carotovora l-asparaginase grown in the presence of 10 mM sodium l-glutamate. 
